Psoriasis induits par les chimiothérapies anti-PD1
J. Bonigen(Société Française de Médecine Vasculaire), E. Mahé(Centre Hospitalier Victor Dupouy), Arnaud Breton, Thomas Hubiche(Centre Hospitalier Intercommunal de Fréjus Saint-Raphaël), G. Jeudy(CHU Dijon Bourgogne), Delphine Bonnet(Centre National de la Recherche Scientifique), M. Pérol(Centre Léon Bérard), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), P. Combemale(Centre Léon Bérard), J. Hureaux(Inserm), E. Gérard(Université de Bordeaux), Christine Raynaud-Donzel(Centre Hospitalier Victor Dupouy), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), N. Kramkimel(Délégation Paris 5), C. Bédane(Central Michigan University), M.‐L. Sigal(Société Française de Médecine Vasculaire), Astrid Blom(Université de Versailles Saint-Quentin-en-Yvelines)
Cited by 2
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
|Journal of Clinical Oncology|2015|419